Patents Assigned to Merus N.V.
-
Publication number: 20230160105Abstract: Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.Type: ApplicationFiled: August 5, 2022Publication date: May 25, 2023Applicant: Merus N.VInventors: Mark THROSBY, Ton LOGTENBERG, John DE KRUIF
-
Publication number: 20230159645Abstract: The present disclosure relates to a multispecific binding moiety comprising a PD-1 binding domain and a TGF-?RII binding domain, wherein the PD-1 binding domain blocks PD-1 mediated signaling and the TGF-?RII binding domain blocks TGF-?RII-mediated signaling. The present disclosure further relates to a pharmaceutical composition comprising such multispecific binding moiety, a method of treatment using such multispecific binding moiety, and a cell producing such multispecific binding moiety.Type: ApplicationFiled: November 18, 2022Publication date: May 25, 2023Applicants: MERUS N.V., Incyte CorporationInventors: Cecilia Anna Wilhelmina GEUIJEN, Patrick Mayes, Shaun M. Stewart, Liang-Chuan Wang
-
Patent number: 11559049Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: January 12, 2018Date of Patent: January 24, 2023Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui D. Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Publication number: 20220380440Abstract: The invention relates to a truncated multivalent multimer comprising two or more binding domains, wherein each binding domain binds a different antigen or epitope, and wherein two of said binding domains are paired via a hinge region, wherein the multimer lacks a CH2 or CH3 region. The present invention further comprises two polypeptides that are paired at or near their respective C-terminus comprising two or more disulfide bridges, wherein each of said polypeptide comprise a variable binding domain, comprising a variable region, wherein each variable region binds the same or different antigens or epitopes on an antigen.Type: ApplicationFiled: December 30, 2019Publication date: December 1, 2022Applicant: Merus N.V.Inventor: Cornelis Adriaan DE KRUIF
-
Publication number: 20220372166Abstract: The invention relates to a treatment using a bispecific antibody that comprises a first antigen-binding site that binds an extracellular part of ErbB-2 and a second antigen-binding site that binds an extracellular part of ErbB-3 for subjects that have cancer that has progressed after receiving a prior treatment. The prior treatment comprises a chemotherapy, a monospecific bivalent antibody comprising antigen-binding sites that bind an extracellular part of ErbB-2 or an extracellular part of ErbB-3, or a prior treatment with a tyrosine kinase inhibitor (TKI) of ErbB-2 or with a combination thereof.Type: ApplicationFiled: October 23, 2020Publication date: November 24, 2022Applicant: Merus N.V.Inventors: Ernesto Isaac WASSERMAN, Leonardo Andres SIRULNIK
-
Publication number: 20220356251Abstract: The invention relates to heavy chain variable regions, binding domains and antibodies specific for human CD3, and CD3 binding proteins. The invention further relates to the use of a CD3 binding protein, preferably an antibody, of the invention in the treatment of cancer or autoimmune disease.Type: ApplicationFiled: March 27, 2020Publication date: November 10, 2022Applicant: Merus N.V.Inventor: Pieter Fokko VAN LOO
-
Publication number: 20220348683Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.Type: ApplicationFiled: February 18, 2022Publication date: November 3, 2022Applicant: Merus N.V.Inventors: Cecilia Anna Wilhelmina GEUIJEN, Cornelis Adriaan DE KRUIF, Mark THROSBY, Ton LOGTENBERG, Alexander Berthold Hendrik BAKKER
-
Patent number: 11445710Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: January 12, 2018Date of Patent: September 20, 2022Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui D. Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Patent number: 11408095Abstract: Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.Type: GrantFiled: April 17, 2020Date of Patent: August 9, 2022Assignee: Merus N.V.Inventors: Mark Throsby, Ton Logtenberg, John De Kruif
-
Publication number: 20220127375Abstract: The invention relates to means and methods of producing at least two antibodies. Methods may include providing cells with nucleic acid that encodes the antibodies; culturing said cells; collecting the antibodies from the culture; and separating produced antibodies from half antibodies by ion exchange chromatography (IEX). In some embodiments the antibodies exhibit IEX retention times that that deviate by 10% or less from the average of the retention times of the individual antibodies under the IEX conditions used. The invention also relates to compositions of antibodies thus produced. In some aspects the invention relates to compositions comprising 2-10 recombinant antibodies characterized in that the IEX retention times of at least two of said antibodies deviate by 10% or less from the average of the retention times of the individual antibodies under the IEX conditions.Type: ApplicationFiled: February 13, 2020Publication date: April 28, 2022Applicant: Merus N.V.Inventors: Robert Paul DOORNBOS, Alexander Berthold Hendrik BAKKER
-
Publication number: 20220127376Abstract: The invention provides a composition comprising two or more binding moieties wherein each of each of said binding moieties comprises a variable domain that binds to an extracellular part of EGFR; and wherein a first of said binding moieties comprises a variable domain that binds to an extracellular part of HER2 and a second of said binding moieties comprises a variable domain that binds to an extracellular part of HER3. The invention also relates to means and method for producing compositions and for the treatment of subjects with the compositions.Type: ApplicationFiled: February 13, 2020Publication date: April 28, 2022Applicant: Merus N.V.Inventors: Cecilia Anna Wilhelmina GEUIJEN, Tristan Louis Jean GALLENNE, Mark THROSBY, Cornelis Adriaan DE KRUIF
-
Patent number: 11279770Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.Type: GrantFiled: February 27, 2015Date of Patent: March 22, 2022Assignee: Merus N.V.Inventors: Cecilia Anna Wilhelmina Geuijen, Cornelis Adriaan De Kruif, Mark Throsby, Ton Logtenberg, Alexander Berthold Hendrik Bakker
-
Publication number: 20220073649Abstract: A binding domain or a multimer or a variant thereof which comprises a variable region encoded by a nucleic acid based on, derived or obtained from an animal phylogenetically distal from a human, which variable region is paired with a human variable region.Type: ApplicationFiled: December 27, 2019Publication date: March 10, 2022Applicant: Merus N.V.Inventor: Cornelis Adriaan DE KRUIF
-
Patent number: 11237165Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: July 18, 2017Date of Patent: February 1, 2022Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
-
Publication number: 20220010013Abstract: The disclosure relates to means and methods of treating a subject for a CLEC12A positive cancer. In some embodiments the method comprises treating the subject in need thereof with two or more administrations of a bispecific antibody that binds CD3 and CLEC12A, wherein in a first administration an first amount of the bispecific antibody is administered and wherein in each of the subsequent administrations the amount of bispecific antibody is higher than the amount of bispecific antibody in the first administration. In some embodiments CLEC12A positive cancer treatment methods are provided at intervals and dosing regimens that spare hemopoietic stem cell compartment allowing for recovery of normal CLEC12A positive hemopoietic cells.Type: ApplicationFiled: December 20, 2019Publication date: January 13, 2022Applicant: Merus N.V.Inventors: Alexander Berthold Hendrik BAKKER, Comellis Jacob Johannes Georgr BOL, Pieter Fokko VAN LOO, Lenardo Andres SIRULNIK, Emesto Isaac WASSERMAN
-
Publication number: 20210155698Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 p M for inhibiting EGER and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC 3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.Type: ApplicationFiled: October 21, 2020Publication date: May 27, 2021Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark Throsby, Robertus Cornelis Roovers
-
Patent number: 10966411Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: October 19, 2009Date of Patent: April 6, 2021Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
-
Patent number: 10934571Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: GrantFiled: April 4, 2016Date of Patent: March 2, 2021Assignee: Merus N.V.Inventors: Patricius Hendrikus Van Berkel, Ronald Hendrik Brus, Abraham Bout, Ton Logtenberg
-
Publication number: 20200384084Abstract: The invention relates to a method of activating a T cell in a subject and to a method of treating a cancer in a subject with a bispecific antibody and IL-15. The invention also relates to a pharmaceutical composition and to a kit comprising the bispecific antibody and IL-15. The invention further relates to a bispecific antibody for use in activating a T cell in a subject, to a bispecific antibody for use in the manufacture of a medicament for activating a T cell in a subject and to a product comprising a bispecific antibody and the mentioned IL-15.Type: ApplicationFiled: November 30, 2018Publication date: December 10, 2020Applicant: Merus N.V.Inventors: Alexander Berthold Hendrik BAKKER, Pieter Fokko VAN LOO
-
Patent number: 10844127Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.Type: GrantFiled: February 27, 2015Date of Patent: November 24, 2020Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robertus Cornelis Roovers